爱尔兰爵士制药去纤苷是治什么的？

(Defibrotide, DF) is a single-chain sodium salt of polydeoxyribonucleoside, which has anti-thrombotic, anti-ischemic, anti-inflammatory and fibrinolytic properties. There are reports abroad that the application of defibrotide in the treatment of severe hepatic veno-occlusive disease (HVOD) is effective without significant toxicity.

In 2000, a European research group (including 19 treatment centers) reported the efficacy of 40 patients with HVOD using Irish Jazz Pharmaceuticals' defibrotide, 28 of whom were patients with severe HVOD or multiple organ failure. The dosage of defibrotide is 10-40 mg/kg/d, the median application time is 18 (2-71) days, and the median time of starting medication is +14 (-2-+53) days after transplantation. The results showed that 22 cases (55%) had complete remission, and 17 cases (43%) survived +100 days.

In 2002, a multi-center collaborative group in the United States reported the results of using defibrotide in 87 patients with severe HVOD and multiple organ failure after hematopoietic stem cell transplantation. The dosage was 5-60 mg/kg/d, and the median time of medication was 15 days. As a result, 36% of the patients had complete remission, and 35% of the patients survived 100 days after transplantation. Both studies showed that defibrotide has no obvious toxic side effects and is a safe and effective drug for the treatment of HVOD. Based on its curative effect, patients can purchase and use it with confidence.

Irish Jazz Pharmaceuticals, the company to which Defibrotide belongs, is a biopharmaceutical company. The company is committed to developing and commercializing products that address unmet medical needs and has a diverse portfolio of products and product candidates targeting the sleep and hematology/oncology areas. Defibrotide was first developed by Gentium Pharmaceuticals of Italy. After Gentium Pharmaceuticals was acquired by Jazz Pharmaceuticals of the United States, it was approved for sale in the United States by the U.S. Food and Drug Administration (FDA) on March 30, 2016.

Recommended hot articles: /newsDetail/87130.html